DCM
DAFNA Capital Management Portfolio holdings
AUM
$405M
1-Year Est. Return
24.52%
1 Year Est. Return
+24.52%
AUM
$362M
AUM Growth
+$9.59M
(+2.7%)
Holding
86
Top Buys
| 1 | +$2.11M | |
| 2 | +$1.37M | |
| 3 | +$1.04M | |
| 4 |
BCAX
Bicara Therapeutics
BCAX
|
+$975K |
| 5 |
Day One Biopharmaceuticals
DAWN
|
+$961K |
Top Sells
| 1 | +$3.31M | |
| 2 | +$3.05M | |
| 3 | +$2.12M | |
| 4 |
UroGen Pharma
URGN
|
+$1.96M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$1.93M |
Sector Composition
| 1 | Healthcare | 85.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Cardiff Oncology
CRDF
$141M
| – | – |
-150,000
|
|
||
77
Lineage Cell Therapeutics
LCTX
$417M
| – | – |
-2,511,374
|
|
||
|
RGLS
78
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-847,176
|
|
||
|
SAGE
79
DELISTED
Sage Therapeutics
SAGE
| – | – |
-108,200
|
|
||
80
Spero Therapeutics
SPRO
$138M
| – | – |
-125,000
|
|
||
81
ARS Pharmaceuticals
SPRY
$763M
| – | – |
-95,290
|
|
||
82
Tenaya Therapeutics
TNYA
$215M
| – | – |
-47,319
|
|
||
83
Taysha Gene Therapies
TSHA
$1.15B
| – | – |
-522,500
|
|
||
|
TSVT
84
DELISTED
2seventy bio
TSVT
| – | – |
-429,252
|
|
||
|
NVRO
85
DELISTED
NEVRO CORP.
NVRO
| – | – |
-38,000
|
|